Tevogen.AI Head Discusses Company's Bold Strategy to Shape the Future of T Cell Therapies at Longwood Spring MIT Conference [Yahoo! Finance]
![Yahoo! Finance](../../../Content/images/providers/Yahoo! Finance.png)
Tevogen Bio Holdings Inc. (TVGN)
Company Research
Source: Yahoo! Finance
immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, highlights the commentary of Mittul Mehta, Tevogen's Chief Information Officer and Head of Tevogen.AI, at the Longwood Spring MIT Conference. Mehta emphasized the transformative potential of Tevogen Bio's innovative T cell technology and the company's groundbreaking approach to overcoming industry challenges. Key Points from Mehta's Commentary Realizing the Full Potential of T Cell Therapies. Mehta emphasized that the full potential of T cell-based therapies remains untapped due to various limitations, including the imbalance between the cost of manufacturing and reimbursement rates. Development of a New Class of T Cell Therapies. Mehta highlighted that Tevogen is leading the development of a potential new class of T cell therapies for treatment of acute viral infections, long-term consequences of viral infections such as Long COVID, viral- and
Show less
Read more
Impact Snapshot
Event Time:
TVGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TVGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TVGN alerts
High impacting Tevogen Bio Holdings Inc. news events
Weekly update
A roundup of the hottest topics
TVGN
News
- Tevogen Bio Holdings Inc. (NASDAQ: TVGN) was given a new $4.20 price target on by analysts at Fundamental Research. They now have a "buy" rating on the stock.MarketBeat
- Tevogen Bio Files Registration Statement for Previously Disclosed Securities; Does Not Relate to Any Previously Undisclosed New Issuances of Dilutive Securities [Yahoo! Finance]Yahoo! Finance
- Tevogen Bio Files Registration Statement for Previously Disclosed Securities; Does Not Relate to Any Previously Undisclosed New Issuances of Dilutive SecuritiesGlobeNewswire
- Tevogen Bio Announces Publication of Positive Phase I Clinical Trial Results for TVGN 489 in Blood Advances [Yahoo! Finance]Yahoo! Finance
- Tevogen Bio Announces Publication of Positive Phase I Clinical Trial Results for TVGN 489 in Blood AdvancesGlobeNewswire
TVGN
Sec Filings
- 6/21/24 - Form S-1
- 6/21/24 - Form 8-K
- 6/13/24 - Form 4
- TVGN's page on the SEC website